Axsome Therapeutics (AXSM) Return on Invested Capital (2023 - 2026)

Axsome Therapeutics' Return on Invested Capital history runs 4 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (up 1.0% YoY), while the FY2025 annual figure was 0.0%, up 1.0% from the prior year.
• Return on Invested Capital came in at 0.0% for Q1 2026 at Axsome Therapeutics, down from 0.0% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q4 2025 to a low of 0.01% in Q4 2024.
• A 4-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Invested Capital.
• Across the five-year window, Return on Invested Capital retreated 1 bps in 2024 and increased 1 bps in 2025, its largest moves.
• Axsome Therapeutics' Return on Invested Capital stood at 0.01% in 2023, then tumbled by 141 bps to 0.01% in 2024, then surged by 86 bps to 0.0% in 2025, then tumbled by 71 bps to 0.0% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.0%, 0.0%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison